Drugs / YJ001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06361108 | May 2024 → Dec 2025 overdue | diabetic polyneuropathy | Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05451667 | Aug → Dec 2022 | — | Yuejia Pharmaceuticals (USA), Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YJ001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06361108 ↗ |
| Route | Topical | “topically administered YJ001” NCT05451667 ↗ |